Tremor and Other Hyperkinetic Movements

Tremor Other Hyperkinet Mov (N Y). 6: 355

Neuroferritinopathy: Pathophysiology, Presentation, Differential Diagnoses and Management

Niraj Kumar¹, Philippe Rizek¹, Mandar Jog¹*

Ruth Walker

1. Department of Clinical Neurological Sciences, Western University, London, ON, Canada

James J. Peters Veterans Affairs Medical Center, Mount Sinai School of Medicine, USA

*To whom correspondence should be addressed. E-mail: mandar.jog@lhsc.on.ca

Copyright © 2016 Kumar et al

DOI: 10.7916/D8KK9BHF

Published online: 08 March 2016

Abstract

Background

Neuroferritinopathy (NF) is a rare autosomal dominant disease caused by mutations in the ferritin light chain 1 (FTL1) gene leading to abnormal excessive iron accumulation in the brain, predominantly in the basal ganglia.

Methods

A literature search was performed on Pubmed, for English-language articles, utilizing the terms iron metabolism, neurodegeneration with brain iron accumulation, and NF. The relevant articles were reviewed with a focus on the pathophysiology, clinical presentation, differential diagnoses, and management of NF.

Results

There have been nine reported mutations worldwide in the FTL1 gene in 90 patients, the most common mutation being 460InsA. Chorea and dystonia are the most common presenting symptoms in NF. There are specific features, which appear to depend upon the genetic mutation. We discuss the occurrence of specific mutations in various regions along with their associated presenting phenomenology. We have compared and contrasted the commonly occurring syndromes in the differential diagnosis of NF to guide the clinician.

Discussion

NF must be considered in patients presenting clinically as a progressive movement disorder with variable phenotype and imaging evidence of iron deposition within the brain, decreased serum ferritin, and negative genetic testing for other more common movement disorders such as Huntington’s disease. In the absence of a disease-specific treatment, symptomatic drug therapy for specific movement disorders may be used, although with variable success.

Introduction

Neuroferritinopathy (NF) is an autosomal dominant, late-onset basal ganglia disorder resulting from mutations in the gene for ferritin light chain 1 (FTL1) on chromosome 19q13.¹,² The pathogenic mutations in the FTL1 gene cause pathological iron deposition and ferritin inclusions in various brain regions, respecting the pattern observed in normal aging.¹ NF belongs to the group of disorders collectively known as neurodegeneration with brain iron accumulation (NBIA). The NBIAs present as a progressive extrapyramidal syndrome with abnormally increased iron deposition in the brain, particularly affecting the basal ganglia.³ Pantothenate kinase-associated neurodegeneration (PKAN) and PLA2G6-associated neurodegeneration are the two most common disorders in this group. NF is one of only two disorders in this expanding group of NBIAs caused by a mutation in genes directly involved in iron metabolism; the other being aceruloplasminemia.⁴ It is the only autosomal dominant NBIA disorder, and patients present late in adulthood with combinations of movement disorders.² To date, 90 cases of NF have been identified with nine causative mutations. On the basis of recent advances in our knowledge about NF, we review the various aspects of NF, namely the pathophysiology, genetics, clinical manifestations, differential diagnosis, treatment options, and prognosis.

Pathophysiology

The brain requires iron for many of its essential activities including transport of oxygen, energy generation, development of oligodendrocytes, myelin synthesis, production of neurotransmitters (dopamine, serotonin, and norepinephrine), and metabolism of nitric oxide.⁵,⁶ The brain contains about 30–40 mg of iron, which forms less than 1% of the total iron in our body.⁷ Disturbances in the homeostatic mechanisms of iron metabolism cause oxidative stress and cellular damage.⁶ Iron content in the brain increases with age, but it is still unclear whether its accumulation in neurodegenerative disorders is a primary or a secondary phenomenon.³,⁴ The distribution of iron in the brain is not homogeneous. The basal ganglia (caudate, putamen, and globus pallidus) have the highest iron concentrations, while the cortex, brainstem, and cerebellum have relatively lower concentrations.⁶,⁸ Iron is mainly stored intracellularly in the ferritin complex; however, in the substantia nigra and locus ceruleus, neuromelanin is the major iron storage molecule.⁴

To get into the brain, iron needs to cross the blood–brain barrier and blood–cerebrospinal fluid (CSF) barrier. Iron is transported by transferrin (Tf), which binds to transferrin receptors (TfR) on the cell surface.⁹ Of the two TfRs (TfR1 and TfR2), TfR1 plays the primary role in iron transfer.⁹ The Tf–TfR system is mainly responsible for exporting iron from the vascular lumen into the vascular endothelial cells. Iron is exported out of the basolateral membrane through some unknown transporters, which may involve ferroportin.⁶ Extracellular iron then enters the astrocytes as low molecular weight complexes (e.g. citrate, adenosine triphosphate, ascorbate) or it may enter the neurons via the Tf–TfR pathways (Figure 1).⁹ Iron can be stored as ferritin in astrocytes and released through ferroportin and ceruloplasmin, the ferroxidase that oxidizes ferrous iron.¹⁰ Astrocytes are ideally positioned to take up iron from the circulation and disperse it among other central nervous system cells.¹⁰

Figure 1 View larger version Figure 1. Cellular Iron Metabolism in the Central Nervous System and Abnormalities in Neuroferritinopathy. Adapted from Dringen et al.¹⁰, Schneider et al.³ and Levi and Finazzi.¹² Transferrin (Tf)-bound ferric iron (Fe³⁺) enters the cell (astrocyte) through adenosine triphosphate (ATP)-dependent transferrin receptor (TfR)-mediated endocytosis, and ferrous iron (Fe²⁺) via a divalent metal transporter 1 (DMT1). STEAP 3, a ferrireductase, converts Fe³⁺ to Fe²⁺. Excess iron is stored in ferritin as Fe³⁺. Fe²⁺ is exported out via ferroportin (FP), where it is oxidized by ceruloplasmin (CP) to Fe³⁺ and is available for other central nervous system cells, i.e., neurons and oligodendrocytes. The solid arrows show the normal iron metabolic pathways and the dotted arrows depict the pathogenic mechanisms in neuroferritinopathy (NF). The FTL1 gene mutation reduces the effectiveness of iron incorporation in ferritin and causes faster ferritin degradation. In turn, the increase in cytosolic iron induces upregulation of the abnormal ferritin. This stimulates production of reactive oxygen species (ROS) and oxidative damage leading to proteasome impairment and cell death. H, Heavy Subunit; L, Light Subunit.

Ferritin, the major iron storage protein, has a spherical shell with an internal cavity that can store 4,500 iron atoms.¹¹ It is composed of two subunit types, heavy (H) and light (L), which are encoded by genes on chromosomes 11 and 19, respectively.⁷,¹¹ Both H and L chains are essential as the heteropolymers assimilate iron more effectively than homopolymers.¹² In NF, the mutations produce a lengthening of the C terminus of the L chain that impairs its normal interaction with the heavy chain, thereby impairing the iron-binding capacity of ferritin.¹¹,¹³ This results in accumulation of ferrous or free iron (Fe²⁺), which causes damage by producing free radicals, and a compensatory upregulation of ferritin production (Figure 1).¹,¹³ Oxidative stress leads to neurodegeneration.¹² Mitochondrial dysfunction may also contribute to the cellular dysfunction in NF probably by affecting neuronal intramitochondrial iron handling.²,¹⁴–¹⁶

Curtis et al. were the first group to report NF cases in a large north England family from the Cumbria region who had dominantly inherited, adult-onset basal ganglia disease.¹ They found a mutation of an adenine insertion at position 460–461 in exon 4 of the FTL1 gene, which caused a frameshift and led to alterations at the C terminus of the gene product. The number of reported cases and mutations in NF are gradually increasing, thus underlining the fact that NF is neither purely confined to the population of north England nor confined to a common founder, as was once thought (Table 1).²,¹³,¹⁴,¹⁶–²² Most FTL1 mutations are located on exon 4, commonly resulting in a frameshift, suggesting that this part of the gene is particularly vulnerable to mutation.¹¹

See full table Table 1. Summary of the Genetics, and Clinical and Radiological Features of All Reported Neuroferritinopathy Cases

Clinical features

NF usually presents in the second to fifth decade of life with the mean age of onset being around 40 years.¹,²,¹³,¹⁵,¹⁹ Those with mutations other than 460InsA appear to have an earlier age of onset (Table 1). The gender of the patients does not affect the age of disease onset or clinical phenotype. Although no predilection was seen for any gender in the largest series,² some series report male predominance.¹⁹,²⁷,³¹ It was suggested that females might be less vulnerable to abnormal iron deposition owing to menstruation,¹⁹ which may explain an asymptomatic 40-year-old female carrier in one of the reports.¹⁷ The disorder is thought to be fully penetrant by the age of 60.²,³³ Clinical presentation does not differ with the age of onset. A strong family history is reported in most of the series.¹,²,¹³ The disease progresses gradually, first involving basal ganglionic and/or cerebellar functions, and spreads to involve cortical functions in the late stages.¹³ The clinical manifestations vary among NF patients, which may be related to the variability in length of the mutant polypeptide and the resulting dominant negative effect of the modified last alpha-helix domain.¹⁴ However, there is no known correlation between the length of the mutant polypeptide and the age of onset. Environmental factors like dietary iron intake and other genes influencing iron metabolism may affect the clinical picture.²¹

Motor symptoms

NF may present with varied movement disorders. Three of the 90 cases reported to date were asymptomatic,²,¹⁷ and clinical data were not available for four additional reported NF patients.¹³,³¹ On analyzing all the symptomatic reported cases of NF (n = 83; Figure 2), we found chorea (39.7%; n = 33) and dystonia (38.5%; n = 32) to be the commonest presenting features; however, these were not specific for any particular FTL1 mutation or a geographical region. Parkinsonism (6%; n = 5) and tics (1.2%; n = 1) as initial presentation were seen in only those patients with 460InsA mutations. Tremor (7.2%; n = 6) at the disease onset was seen in patients of French ancestry with 498InsTC, and in Japanese patients with 469_484dup16nt. The 469_484dup16nt mutation is also seen in Italy, presenting with similar clinical features. Cerebellar ataxia (4.8%; n = 4) as the presenting movement disorder was common in patients of French ancestry with 498InsTC mutations. Those with 460InsA mutations are unlikely to present with tremor and cerebellar ataxia.

Figure 2 View larger version Figure 2. Initial Presentations of Neuroferritinopathy Patients with Respective Mutations in Reported Symptomatic Cases. Chorea (39.7%) and dystonia (38.5%) are the most common initial presentations, followed by tremor (7.2%), parkinsonism (6%), cerebellar ataxia (4.8%), psychiatric symptoms (2.4%) and tics (1.2%). The associated mutations are listed alongside the symptoms.

The abnormal movements may remain asymmetric throughout the disease course in almost two-thirds of patients.² Irrespective of the initial presentation, most patients develop dystonia (83%), predominantly in the lower limbs, and/or chorea (70%).² Cerebellar symptoms such as dysmetria, ataxia, and palatal tremor are reported in patients with NF and may appear at any stage of the disease.²,¹³,¹⁴,¹⁶,¹⁷,²⁰,²²,²³,²⁶,³¹ Although unsteady gait and repeated falls may appear early in NF,¹⁴,²⁷ the majority of patients remain mobile even after 20 years of disease onset.² Patients with dystonic presentation have the most severe physical disability.² Dysarthria and dysphagia have been reported in many patients.²,¹⁶,¹⁹,²⁰,²²,²⁶,²⁷,³⁰,³⁴ Oromandibular dyskinesia (65%), impairment of voice and speech (dysarthrophonia) with action-specific facial dystonia (63%) are commonly seen,²,¹³,²⁰,²²,²⁴ and felt by one group to be specific to NF.²⁴ Facial tics may be seen.²⁶ Although changes in handwriting are expected to occur in most of the patients, micrographia has been specifically reported.¹⁶ Rarely, patients may present with ballistic movements,² alien limb phenomenon,² blepharospasm,²,²⁴,³⁰ or writer’s cramp.²

Pyramidal signs including spasticity,¹ brisk deep tendon reflexes,³² and Babinski signs¹³,¹⁶,²² have been reported in patients with NF. Hypotonia may be seen.¹⁹,²²,³² Although extraocular movements are usually well preserved, some patients may develop saccadic pursuit,²,¹⁶,²³ slow saccades,¹⁶,²²,²³ and apraxia of eyelid opening.¹⁶,²³ Limitation of vertical eye movements²⁰ and horizontal oculomotor dysmetria²¹ are reported.

Cognitive decline and psychiatric symptoms

The onset of cognitive impairment may vary from the first decade to more than three decades after the onset of motor symptoms.²,¹³–¹⁵,¹⁹,²¹,²⁵,³²,³⁴ One study reported neurocognitive features presenting within 5 years of onset of the motor manifestations.³⁴ Mild deficits in verbal fluency may be seen early.² Features suggestive of frontal and subcortical cognitive impairment like disinhibition, reduced verbal fluency, executive dysfunction (working memory), and attention difficulties predominate.²,¹³,¹⁵,²¹,²⁵ Rarely, patients may present with psychiatric symptoms (2.4%; n = 2) (Figure 2). Japanese patients presented more commonly with psychiatric symptoms and cognitive decline. Anxiety,¹³ paranoid delusions,³⁵ acute psychosis,¹⁷ or depression¹⁶,¹⁹,²⁰ have been reported to occur anytime in the course of NF.

Other features

Sleep disturbances, including insomnia,¹³ sleep apnea,³⁵ and central sleep apnea with restrictive respiratory insufficiency causing excessive daytime sleepiness,²⁰ have been reported. Other features may include areflexia and a positive Romberg test;¹⁶ features of dyautonomia such as othostatic hypotension,²⁰,²² constipation,²⁰ urinary incontinence²⁰ and impotence;¹⁶ fatigue¹⁴ and pseudobulbar effect.¹⁶,¹⁹,²² Chronic headache may also be a presenting symptom.²² Sensory abnormalities in the large fiber sensations (vibration and proprioception) and positive frontal release signs have been reported.²⁶

Differential diagnoses

The varied clinical presentations of NF make for a long list of differential diagnoses. Common differential diagnoses are listed in Table 2. Others may include Niemann–Pick type C (NPC) and mitochondrial disease.² Marked supranuclear gaze impairment favors a diagnosis of NPC.² Although there are overlaps in the clinical, radiological, and muscle biopsy findings between NF and mitochondrial disorders, positive genetic testing for FTL1 mutation confirms the diagnosis of NF.² Additional brain immunocytochemical abnormalities indicate a secondary defect of the respiratory chain in NF.¹⁶ Early in the course of NF, patients may present with features of writer’s cramp, blepharospasm, or restless leg syndrome.² A family history of NF, decreased serum ferritin, and magnetic resonance imaging (MRI) brain suggestive of abnormal iron storage in the basal ganglia may point to the diagnosis of NF in such patients.²

See full table Table 2. Common Differential Diagnoses of Neuroferritinopathy

Investigations

Laboratory investigations

Complete blood count, renal function tests, copper studies (serum ceruloplasmin and copper, and 24-hour urinary copper), and serum creatine kinase are typically normal in NF.¹,²,¹⁵,²³,³⁵ Liver function tests may be abnormal.¹³ Serum ferritin levels may be decreased¹,²,¹⁴,¹⁷,²⁰,²¹,³² or in the normal range.¹⁶,¹⁹,²²,²³,³⁵ Although decreased serum ferritin was not uniformly seen in all the cases, a low serum ferritin in the setting of an unknown movement disorder with autosomal dominant family history suggests the diagnosis of NF. In the largest series of patients, the serum ferritin was decreased in 82% of males and all postmenopausal females, but only in 23% of premenopausal females.² This may be explained because of the loss of iron owing to menstruation in premenopausal females.²,¹⁹ Decreased CSF ferritin was reported by Nishida et al.²² Nerve conduction studies are normal.²³

Neuroimaging

Key features on brain imaging support the diagnostic consideration of NF.¹¹ Features of iron deposition precede evidence of atrophy and necrosis on brain MRI.²⁹,³⁶ Brain MRI may show basal ganglia cavitation or cystic changes (predominantly in the globus pallidus and putamen),¹,¹⁵,¹⁶,¹⁸,²⁰,²¹,²⁸,²⁹,³⁶ hyperintensity with surrounding hypointensity on T2-weighted imaging involving the putamen, pallidum, thalamus, substantia nigra, and the dentate nucleus,²,¹⁸,¹⁹,²²,²³,³⁵ cortical atrophy,¹³,¹⁴,¹⁷,²³,³¹ pontine atrophy,¹³ and cerebellar atrophy.¹³,¹⁶,²⁸,³¹ T2-weighted images showing a hypointense rim with hyperintense center in the globus pallidus (“eye of the tiger sign”), considered pathognomic of PKAN,³ is reported in NF.²²,³⁶ This MRI signature may also be seen in cortico-basal ganglionic degeneration, multiple system atrophy, progressive supranuclear palsy, and pure akinesia with gait freezing.²²,³⁶ While thalamic iron stores correlate with the severity of dystonia,²⁹ voxel-based analysis showed correlation between caudate iron stores and globus pallidus cavitation to the severity in NF patients.²⁸ Iron deposition in the cortex,²⁸,³⁰,³⁶ on susceptibility-weighted imaging sequence on MRI, produces a hypointense fine signal band along the cortical contours and is termed “pencil-lining.”³⁰ Patients older than 50 years of age or those with disease duration of more than 10 years develop more severe basal ganglia cavitation.²⁹ Rarely, the brain MRI may be normal in the initial stage of the disease.³⁵ Asymptomatic persons with positive gene mutation may have abnormal brain MRI.¹⁷ MRI brain findings in some patients with NF may remain asymmetric.¹⁶,²¹,²⁵

Genetic testing

Genetic testing for the FTL1 gene mutation on chromosome 19q13.3 is confirmatory.¹¹ Rarely, the individual may be asymptomatic despite a confirmed mutation.²,¹⁷ Of the nine causative FTL1 mutations reported to date, 460InsA is the most common in patients of British descent and 498InsTC is common in patients with French ancestry. The 460InsA mutation has not been found in Japanese patients.

Neuropathology

Mild cerebral and cerebellar atrophy with basal ganglia cavitation and numerous iron-positive inclusions especially in the globus pallidus and putamen are seen on neuropathological examination.¹,¹³,¹⁶ Intranuclear and intracytoplasmic ferritin deposition in astrocytes and oligodendroglia are seen in the caudate nucleus, putamen, globus pallidus, and in gray and white matter regions.¹³,¹⁶ Ferritin deposits are also seen in cerebellar granule cells and Purkinje cells.¹³ The ferritin deposits may be seen in the parenchymal cells of other organs like skin fibroblasts, renal tubule cells, and endothelial cells of muscle capillaries.¹³ Intranuclear iron and ferritin inclusions are also found in hepatocytes.¹⁶ This points to the fact that the pathology of NF is not limited to the brain tissue only and some authors suggested that “hereditary ferritinopathy” is a better term than the more restrictive “neuroferritinopathy.”⁴,¹³,¹⁶ Muscle biopsy in a few NF patients showed evidence of mitochondrial respiratory chain defects.²,¹⁴–¹⁶ Chinnery et al.² found a higher percentage of cytochrome c oxidase negative fibers than expected for age in two out of nine NF patients who underwent muscle biopsy. Respiratory chain complex assays reported in eight patients found isolated or combined defects in seven of them. While isolated defects in complex I² and complex III¹⁴ were seen in three and one patient respectively, three other patients had a combined defect involving multiple respiratory chain complexes.²,¹⁶ A generalized deficiency was reported in a sample of post-mortem cerebellar tissue.¹⁶ These respiratory chain defects suggest mitochondrial dysfunction in NF.

Management

At present, there are no established guidelines or specific management recommendations for patients with NF.²⁷ An individualized symptomatic approach to treatment is recommended. A number of drugs have been used for symptomatic management in NF with variable success. Dystonia either showed some²,²¹,²³,³⁵ or no¹⁴,¹⁶,¹⁹,²² improvement with anticholinergics such as trihexyphenidyl. While variable improvement in chorea, tics, and stereotypy were reported with sulpiride (D2 receptor blocker) and tetrabenazine (dopamine depleting agent) in some patients, the latter is associated with complications including sedation, parkinsonism, and depression.²,²⁶,²⁷,³⁵ One report showed excellent response of facial tic/stereotype and chorea with tetrabenazine.²⁶ Parkinsonian symptoms of NF showed either no²,²²,²⁷ or only some initial benefit²⁰,³⁵ with levodopa. Benzodiazepines (diazepam, clonazepam, and lorazepam) have been shown to improve dystonia in a few patients,²,³⁵ but not in others.¹⁹,²² Antidepressants, like fluoxetine, were helpful in treating depression.¹⁶,¹⁹ Muscle relaxants, like baclofen, gave either partial³⁵ or no²,²² benefit in treating dystonia. Various other drugs that have failed to improve the movement disorders include risperidone², haloperidol,¹³,¹⁹,²⁷ tiapride,¹⁹ olanzapine,² amitriptyline,²,¹⁶,³⁵ apomorphine,²,³⁵ amantadine,² dopamine agonists,¹⁴ deanol,² dantrolene,² paroxetine,² mirtazapine,² gabapentin,² sodium valproate,²,²² and carbamazepine.²,³⁵ One author reported improvement in the finger dystonia of a patient with herbal medicine (Shakuyaku-kanzo-to).²² Physiotherapy in addition to drugs improved dystonia and gait in one patient.²² Speech amplification may help hypophonia.²

Moderate benefits have been reported with the use of botulinum toxin for dystonia affecting the neck, orofacial region (including blepharospasm), and extremities.²,¹⁶,²¹,³⁵ Other symptomatic treatments include non-invasive positive pressure ventilation for sleep apnea and percutaneous endoscopic gastrostomy feeding for severe weight loss due to dysphagia.²⁰,²⁷ Dysphagia should be monitored and managed with swallowing assessment and dietary modification.²

A number of treatments have been used for modulating the brain iron stores in the hope of reversing the pathology, but none have been reported to be successful. A low-iron diet did not show benefit after 6 months of its institution.¹⁶ Iron chelation therapy with desferrioxamine (4,000 mg weekly subcutaneously for up to 14 months)² and deferiprone (15 mg/kg/day for 6 months) have not been effective.²,¹⁴ No improvement was seen with monthly venesection.²,¹⁶,¹⁹ Although no benefit has been reported in the short term with iron-modulating therapies, the long-term response has yet to be studied.

Although NF progresses gradually but relentlessly in most of the patients,²,¹³ patients with a 458dupA mutation show a relatively rapid progression of parkinsonism, ataxia, and neuropsychiatric symptoms.²⁰ Patients usually die of aspiration pneumonia.¹⁶,¹⁹ Other reported causes of death include community-acquired pneumonia,²⁷ asphyxiation of food,¹⁹ and cardiomyopathy.²⁰ It is not known whether this last cause was related to NF.

Conclusion

NF is a rare autosomal dominant disease with FTL1 mutation leading to abnormal excessive iron accumulation in the brain (predominantly in the basal ganglia) and other organ systems. In people of British descent, the most common mutation is 460InsA. Nine variant mutations in the FTL1 gene have been reported in various geographical regions. NF patients with mutations other than 460InsA appear to have an earlier age of onset. Although NF has heterogeneous clinical presentations, chorea and dystonia are the most common presenting symptoms; however, these are not specific to a mutation. There are however specific features that depend on the genetic mutation and hence on regional distribution as reviewed in this manuscript.

NF must be considered in patients presenting clinically as a relentlessly progressive movement disorder with variable phenotype and imaging evidence of iron deposition within the brain, decreased serum ferritin, and negative genetic testing for other more common movement disorders like Huntington’s disease. The FTL1 gene mutation should be suspected despite the lack of a positive family history, as new genetic mutations of this gene may occur in any population. Brain MRI is helpful, even during the pre-symptomatic period in relatives of affected patients, and unilateral or asymmetric lesions do not exclude the diagnosis. Although MRI features may overlap with other NBIAs, basal ganglia cavitation and cortical “pencil-lining” on susceptibility-weighted imaging favors NF. Standard symptomatic drug treatment for specific movement disorders may be used with variable success. Chelation therapies have not been shown to be effective.

Footnotes

Funding: None.

Financial Disclosures: None.

Conflict of Interests: The authors report no conflict of interest.

Ethics Statement: This study was reviewed by the authors' institutional ethics committee and was considered exempted from further review.

Articles from Tremor and Other Hyperkinetic Movements are provided here courtesy of Center for Digital Research and Scholarship at Columbia University Libraries/Information Services

PMC Copyright Notice

The articles available from the PMC site are protected by copyright, even though access is free. Copyright is held by the respective authors or publishers who provide these articles to PMC. Users of PMC are responsible for complying with the terms and conditions defined by the copyright holder.

Users should assume that standard copyright protection applies to articles in PMC, unless an article contains an explicit license statement that gives a user additional reuse or redistribution rights. PMC does not allow automated/bulk downloading of articles that have standard copyright protection.

See the copyright notice on the PMC site, https://www.ncbi.nlm.nih.gov/pmc/about/copyright/, for further details and specific exceptions.

References

Curtis ARJ, Fey C, Morris CM, et al., authors. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet. 2001;28:350–354. [PubMed]

Chinnery PF, Crompton DE, Birchall D, et al., authors. Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain. 2007;130:110–119. [PubMed]

Schneider SA, Dusek P, Hardy J, Westenberger A, Jankovic J, Bhatia KP, authors. Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Curr Neuropharmacol. 2013;11:59–79. . doi: 10.2174/157015913804999469. [PubMed]

Dusek P, Jankovic J, Le W, authors. Iron dysregulation in movement disorders. Neurobiol Dis. 2012;46:1–18. . doi: 10.1016/j.nbd.2011.12.054. [PubMed]

Crichton RR, Dexter DT, Ward RJ, authors. Brain iron metabolism and its perturbation in neurological diseases. J Neural Transm. 2011;118:301–314. . doi: 10.1007/s00702-010-0470-z. [PubMed]

Ward RJ, Zucca FA, Duyn JH, Crichton RR, Zecca L, authors. The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 2014;13:1045–1060. . doi: 10.1016/S1474-4422(14)70117-6. [PubMed]

Levi S, Cozzi A, Arosio P, authors. Neuroferritinopathy: a neurodegenerative disorder associated with L-ferritin mutation. Best Pract Res Clin Haematol. 2005;18:265–276. [PubMed]

Ramos P, Santos A, Pinto NR, Mendes R, Magalhães T, Almeida A, authors. Iron levels in the human brain: a post-mortem study of anatomical region differences and age-related changes. J Trace Elem Med Biol. 2014;28:13–17. . doi: 10.1016/j.jtemb.2013.08.001. [PubMed]

Leitner DF, Connor JR, authors. Functional roles of transferrin in the brain. Biochim Biophys Acta. 2012;1820:393–402. . doi: 10.1016/j.bbagen.2011.10.016. [PubMed]

Dringen R, Bishop GM, Koeppe M, Dang TN, Robinson SR, authors. The pivotal role of astrocytes in the metabolism of iron in the brain. Neurochem Res. 2007;32:1884–1890. [PubMed]

Levi S, Rovida E, authors. Neuroferritinopathy: from ferritin structure modification to pathogenetic mechanism. Neurobiol Dis. 2015;81:134–143. . doi: 10.1016/j.nbd.2015.02.007. [PubMed]

Levi S, Finazzi D, authors. Neurodegeneration with brain iron accumulation: update on pathogenic mechanisms. Front Pharmacol. 2014;5:1–20. . doi: 10.3389/fphar.2014.00099. [PubMed]

Vidal R, Ghetti B, Takao M, et al., authors. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the ferritin light polypeptide gene. J Neuropathol Exp Neurol. 2004;63:363–380. [PubMed]

Storti E, Cortese F, Di Fabio R, et al., authors. De novo FTL mutation: a clinical, neuroimaging, and molecular study. Mov Disord. 2013;28:252–253. . doi: 10.1002/mds.25275. [PubMed]

Chinnery PF, Curtis ARJ, Fey C, et al., authors. Neuroferritinopathy in a French family with late onset dominant dystonia. J Med Genet. 2003;40:e69 [PubMed]

Mancuso M, Davidzon G, Kurlan RM, et al., authors. Hereditary ferritinopathy: a novel mutation, its cellular pathology, and pathogenetic insights. J Neuropathol Exp Neurol. 2005;64:280–294. [PubMed]

Maciel P, Cruz VT, Constante M, et al., authors. Neuroferritinopathy: missense mutation in FTL causing early-onset bilateral pallidal involvement. Neurology. 2005;65:603–605. [PubMed]

Ohta E, Takiyama Y, authors. MRI findings in neuroferritinopathy. Neurol Res Int. 2012;2012:197438 . doi: 10.1155/2012/197438. [PubMed]

Kubota A, Hida A, Ichikawa Y, et al., authors. A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: description of clinical features and implications for genotype-phenotype correlations. Mov Disord. 2009;24:441–445. . doi: 10.1002/mds.22435. [PubMed]

Devos D, Tchofo PJ, Vuillaume I, et al., authors. Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation. Brain. 2009;132:2008–2010

Moutton S, Fergelot P, Trocello JM, et al., authors. A novel FTL mutation responsible for neuroferritinopathy with asymmetric clinical features and brain anomalies. Park Relat Disord. 2014;20:935–937

Nishida K, Garringer HJ, Futamura N, et al., authors. A novel ferritin light chain mutation in neuroferritinopathy with an atypical presentation. J Neurol Sci. 2014;342:173–177. [PubMed]

Wills AJ, Sawle GV, Guilbert PR, Curtis ARJ, authors. Palatal tremor and cognitive decline in neuroferritinopathy. J Neurol Neurosurg Psychiatry. 2002;73:91–92. . doi: 10.1136/jnnp.73.1.91. [PubMed]

Crompton DE, Chinnery PF, Bates D, et al., authors. Spectrum of movement disorders in neuroferritinopathy. Mov Disord. 2005;20:95–99. [PubMed]

Caparros-Lefebvre D, Destee A, Petit H, authors. Late onset familial dystonia: could mitochondrial deficits induce a diffuse lesioning process of the whole basal ganglia system? J Neurol Neurosurg Psychiatry. 1997;63:196–203. [PubMed]

Ondo WG, Adam OR, Jankovic J, Chinnery PF, authors. Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. Mov Disord. 2010;25:2470–2472. . doi: 10.1002/mds.23299. [PubMed]

Lehn A, Boyle R, Brown H, Airey C, Mellick G, authors. Neuroferritinopathy. Parkinsonism Relat Disord. 2012;18:909–915. . doi: 10.1016/j.parkreldis.2012.06.021. [PubMed]

Keogh MJ, Aribisala BS, He J, et al., authors. Voxel-based analysis in neuroferritinopathy expands the phenotype and determines radiological correlates of disease severity. J Neurol. 2015;262:2232–40. . doi: 10.1007/s00415-015-7832-2. [PubMed]

McNeill A, Gorman G, Khan A, Horvath R, Blamire AM, Chinnery PF, authors. Progressive brain iron accumulation in neuroferritinopathy measured by the thalamic T2* relaxation rate. Am J Neuroradiol. 2012;33:1810–1813. . doi: 10.3174/ajnr.A3036. [PubMed]

Batla A, Adams ME, Erro R, et al., authors. Cortical pencil lining in neuroferritinopathy: a diagnostic clue. Neurology. 2015;84:1816–1818. [PubMed]

Ory-Magne F, Brefel-Courbon C, Payoux P, et al., authors. Clinical phenotype and neuroimaging findings in a French family with hereditary ferritinopathy (FTL498-499InsTC). Mov Disord. 2009;24:1676–1683. . doi: 10.1002/mds.22669. [PubMed]

Ohta E, Nagasaka T, Shindo K, et al., authors. Neuroferritinopathy in a Japanese family with a duplication in the ferritin light chain gene. Neurology. 2008;70:1493–1494. . doi: 10.1212/01.wnl.0000310428.74624.95. [PubMed]

Crompton DE, Chinnery PF, Fey C, et al., authors. Neuroferritinopathy: a window on the role of iron in neurodegeneration. Blood Cells Mol Dis. 2002;29:522–531. [PubMed]

Keogh MJ, Singh B, Chinnery PF, authors. Early neuropsychiatry features in neuroferritinopathy. Mov Disord. 2013;28:1310–1313. . doi: 10.1002/mds.25371. [PubMed]

Mir P, Edwards MJ, Curtis ARJ, Bhatia KP, Quinn NP, authors. Adult-onset generalized dystonia due to a mutation in the neuroferritinopathy gene. Mov Disord. 2005;20:243–245. [PubMed]

McNeill A, Birchall D, Hayflick SJ, et al., authors. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology. 2008;70:1614–1619. . doi: 10.1212/01.wnl.0000310985.40011.d6. [PubMed]

Taly AB, Meenakshi-Sundaram S, Sinha S, Swamy HS, Arunodaya GR, authors. Wilson disease. Medicine (Baltimore). 2007;86:112–121. [PubMed]

Das SK, Ray K, authors. Wilson’s disease: an update. Nat Clin Pract Neurol. 2006;2:482–493. [PubMed]

Walker RH, author. Untangling the thorns: advances in the neuroacanthocytosis syndromes. J Mov Disord. 2015;8:41–54. . doi: 10.14802/jmd.15009. [PubMed]

Martino D, Stamelou M, Bhatia KP, authors. The differential diagnosis of huntington’s disease-like syndromes: “red flags” for the clinician. J Neurol Neurosurg Psychiatry. 2013;84:650–656. . doi: 10.1136/jnnp-2012-302532. [PubMed]

Walker RH, author. Chorea. Continuum (Minneap Minn). 2013;19:1242–1263. . doi: 10.1212/01.CON.0000436155.46909.c3. [PubMed]

Balint B, Bhatia KP, authors. Isolated and combined dystonia syndromes—an update on new genes and their phenotypes. Eur J Neurol. 2015;22:610–617. . doi: 10.1111/ene.12650. [PubMed]

Houlden H, Singleton AB, authors. The genetics and neuropathology of Parkinson’s disease. Acta Neuropathol. 2012;124:325–338. . doi: 10.1007/s00401-012-1013-5. [PubMed]

[Back]

Figure 1. Cellular Iron Metabolism in the Central Nervous System and Abnormalities in Neuroferritinopathy. Adapted from Dringen et al.¹⁰, Schneider et al.³ and Levi and Finazzi.¹² Transferrin (Tf)-bound ferric iron (Fe³⁺) enters the cell (astrocyte) through adenosine triphosphate (ATP)-dependent transferrin receptor (TfR)-mediated endocytosis, and ferrous iron (Fe²⁺) via a divalent metal transporter 1 (DMT1). STEAP 3, a ferrireductase, converts Fe³⁺ to Fe²⁺. Excess iron is stored in ferritin as Fe³⁺. Fe²⁺ is exported out via ferroportin (FP), where it is oxidized by ceruloplasmin (CP) to Fe³⁺ and is available for other central nervous system cells, i.e., neurons and oligodendrocytes. The solid arrows show the normal iron metabolic pathways and the dotted arrows depict the pathogenic mechanisms in neuroferritinopathy (NF). The FTL1 gene mutation reduces the effectiveness of iron incorporation in ferritin and causes faster ferritin degradation. In turn, the increase in cytosolic iron induces upregulation of the abnormal ferritin. This stimulates production of reactive oxygen species (ROS) and oxidative damage leading to proteasome impairment and cell death. H, Heavy Subunit; L, Light Subunit.

[Back]

[Back]

Table 1. Summary of the Genetics, and Clinical and Radiological Features of All Reported Neuroferritinopathy Cases

FTL1 Mutation (In Order of Identification)
Place of Origin (Study)
Number of Cases (M:F)
Mean Onset Age (Years)
Movement Disorders
Co and Np
MRI Brain
Serum Ferritin

D
Ch
Pk
Tr
At
T/S
O

460InsA
UK Chinnery et al.2 It includes cases from other studies1,15,23–25
41 (20:21), incl. 1 asymp.
39.4
+
+
+
+
−
−
+
+

T2 decr. in DN, RN, SN, P, GP, Th, CN

Incr. with surrounding decr. on T2W in P, GP, Th23

Decr.

USA Ondo et al.26
2 (2:0)
48.5
−
+
−
−
+
+
+
−

T2 and flair lesions in the GP and cerebellum

Decr.

Australia (British ancestry) Lehn et al.27
5 (5:0)
47
+
+
+
+
−
+
+
+

SWI showed iron deposition in RN, SN, GP and motor cortex

Decr.

UK Keogh et al.28 McNeill et al.29
10 (5:5)
48.5
+
+
+

−

BG cavitation

T2 decr. in Th29

T1 incr. in CN and decr. in GP

Cerebellar atrophy

Lingual gyrus involvement28

Decr. (n = 8) & low normal (n = 2)

UK Batla et al.30
3 (1:2)
50.7
+
−
+
−
+
−
+
−

SWI showed pencil lining in cerebral and cerebellar cortex

Decr.

498InsTC
France Vidal et al.13 and Ory-Magne et al.31
11 (7:4)
36.8
+
+
+
+
+
−
+
+

T2 decr. and T1 incr. in BG

Decr. (n = 2)

474G→A
Portugal Maciel et al.17
3 (2:1); incl. 2 asymp.
13
−
−
+
−
+
−
−
+

T2 incr. in GP

Cerebral atrophy

Decr.

646InsC
USA (French Canadian and Dutch ancestry) Mancuso et al.16
2 (1:1)
56
+
+
−
−
+
−
+
+

Cerebellar atrophy

T2 incr. in P, GP, CN and SN

Low–normal range

469_484dup16nt
Japan Ohta et al.32
2 (1:1)
Teen-age
−
−
+
+
−
−
−
+

Cystic changes in GP and striatum

T2 incr. in Th, DN, and SN.

Decr.

Italy Storti et al.14
1 (1:0)
Late 20s
+
−
+
+
+
−
−
+

Cavitation of bilateral LN

Cortical atrophy

Decr.

458dupA
France Devos et al.20
1 (0:1) + 3 prev. reported (3:0)2
24–44
+
−
+
−
+
−
+
+

Cystic cavitation in BG

Iron deposition in DN, GP, and P

Decr.

641_642 4bp_dup
Japan Kubota et al.19
7 (7:0)
51.8
+
+
−
+
−
−
+
+

T2 incr. with surrounding decr. in GP and P

Low–normal range

468dupT
France Moutton et al.21
1 (1:0)
27
+
+
−
−
−
−
−
+

BG cavitations

Asymmetrical changes

Decr.

468_483dup16nt
Japan Nishida et al.22
1 (0:1)
42
+
−
−
−
+
−
+
+

T2 incr. with surrounding decr. in bilateral posterior GP and P

Mild cerebral and cerebellar atrophy

Normal serum ferritin; decr. CSF ferritin

Abbreviations: A, Adenine Base; Asymp., Asymptomatic; At, Ataxia; BG, Basal Ganglia; C, Cytosine Base; Ch, Chorea; CN, Caudate Nucleus; Co, Cognitive Impairment; CSF, Cerebrospinal Fluid; D, Dystonia; Decr., Decreased; DN, Dentate Nucleus; Dup, Duplication; GP, Globus Pallidus; Incl., Including; Incr., Increased; Ins, Insertion; LN, Lenticular Nuclei; Np, Neuropsychiatric Manifestations; O, Orofacial Dyskinesia; P, Putamen; Pk, Parkinsonism; Prev., Previously; RN, Red Nucleus; SN, Substantia Nigra; SWI, Susceptibility-weighted Imaging; T, Thymine Base; Th, Thalamus; Tr, Tremor; T/S, Tics/Stereotypy.

[Back]

[Back]

Figure 2. Initial Presentations of Neuroferritinopathy Patients with Respective Mutations in Reported Symptomatic Cases. Chorea (39.7%) and dystonia (38.5%) are the most common initial presentations, followed by tremor (7.2%), parkinsonism (6%), cerebellar ataxia (4.8%), psychiatric symptoms (2.4%) and tics (1.2%). The associated mutations are listed alongside the symptoms.

[Back]

[Back]

Table 2. Common Differential Diagnoses of Neuroferritinopathy

Inheritance Pattern
Disease
Similarities
Differences

Clinical
Radiology
Pathology and Biochem.
Clinical
Radiology
Pathology and Biochem.

Autosomal recessive
PKAN3,36

Ataxia

Dystonia

Tremor

Cognitive decline

T2 decr. in GP

Iron and ferritin deposition in BG

Onset before 6 years in 90%

Early cognitive, psychiatric and bulbar involvement

Oculomotor and retinal abnormalities

Classic “eye of the tiger” sign, central T2 incr. and surrounding decr. in GP

No cavitations

Cortex, brainstem, and cerebellum not involved

Aceruloplasminemia3,36

Dystonia

Dysarthria

Ataxia

Cognitive decline

T2 decr. in GP

Iron deposition in brain (BG, DN, Th, cerebral, and cerebellar cortices)

Diabetes

Anemia

Early cognitive decline

Ataxia more common

Retinal involvement

T2 decr. in DN, SN, CN, P, Th, and cerebral cortex

No cavitation

Iron deposition in retina, pancreas, and liver in all patients

Incr. serum ferritin

Wilson’s disease37,38

Dystonia

Chorea

Parkinsonism

Ataxia

Cortical, cerebellar and BG atrophy

Iron deposition in BG

Putaminal cavitation

Young onset

Early psychiatric and hepatic features

Corneal K-F rings

T2 incr. in P, GP, CN, and Th.

“Face of giant Panda” sign in mid-brain (T2 incr. around RN)

Copper deposition in BG

Decr. serum ceruloplasmin and increased 24-hour urinary copper

Chorea-acanthocytosis39

Chorea

Orofacial dyskinesia

Dystonia

Tics

Parkinsonism

BG atrophy

Neuronal loss and gliosis in the striatum, GP and SN

AR

Young adult onset

Seizures

Tics more common

Self-mutilation

Oculomotor abnormalities

Myopathy

Neuropathy

Caudate atrophy (predilection for the head of CN)

Acanthocytes in peripheral blood smear

Elevated CK

Autosomal dominant
HD4,40

Chorea

Tics

Ataxia

Parkinsonism (Westphal variant)

Mild cortical atrophy

May have iron accumulation in BG

Genetic anticipation¹

Early personality changes and cognitive impairment

Tics common

Caudate atrophy (tail and body of CN)

Atrophy mainly in BG

DRPLA40

Chorea

Ataxia

Cognitive and psychiatric features

Cerebellar atrophy

None specific

Genetic anticipation¹

Epilepsy and myoclonus

Pontine tegmental atrophy

None specific

SCA40,41

Ataxia

Pyramidal signs

Chorea (SCA 17)

Cerebellar atrophy

None specific

Genetic anticipation¹

Marked ataxia

Nystagmus

Peripheral neuropathy

Myoclonus

Seizures

Marked cerebellar atrophy

None specific

Sporadic/mixed (AR and AD)
Isolated or combined dystonia syndromes42

Focal or generalized dystonia

Parkinsonism

None specific

None specific

Childhood onset

Myoclonus

Normal cognition

DRD is levodopa responsive

None specific

None specific

Parkinsonism (IPD, parkin mutation)4,43

Parkinsonism

None specific

Iron deposition may be seen in SN

Levodopa responsive

None specific

None specific

Abbreviations: AD, Autosomal Dominant; AR, Autosomal Recessive; BG, Basal Ganglia; Biochem., Biochemical Parameters; CK, Creatine Kinase; CN, Caudate Nucleus; Decr., Decreased; DN, Dentate Nucleus; DRD, Dopa-responsive Dystonia; DRPLA, Dentato-Rubral-Pallido-Luysian Atrophy; GP, Globus Pallidus; HD, Huntington’s Disease; Incr., Increased; IPD, Idiopathic Parkinson Disease; K-F rings, Kayser–Fleischer Rings; P, Putamen; PD, Parkinson Disease; PKAN, Pantothenate Kinase-associated Neurodegeneration; RN, Red Nucleus; SCA, Spinocerebellar Ataxia; SN, Substantia Nigra; Th, Thalamus.

1. In successive generations, there may be an increase in the number of trinucleotide repeats in the affected gene leading to earlier age of onset.

[Back]